| Nov 14 |
Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial ...
|
| Nov 14 |
Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript
|
| Nov 13 |
Acelyrin files for $400M mixed securities shelf
|
| Nov 13 |
Acelyrin GAAP EPS of -$0.49 beats by $0.32
|
| Nov 13 |
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
|
| Nov 13 |
Earnings Scheduled For November 13, 2024
|
| Nov 6 |
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
|
| Oct 16 |
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
|
| Sep 20 |
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch
|
| Sep 19 |
Acelyrin spikes as late-stage data for lead asset selected for medical event
|
